Allogeneic Response
Allogeneic Response - Related Videos
06:48
Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice
0 Views •
Cited by 10 •
2014
Tail-skin transplantation is a powerful model for studying T cell-dependent rejection and tolerance induction during allogeneic immune responses in mice. The advantages of this protocol are minor invasive surgery, and ease of monitoring with no need to sacrifice the recipient mouse.
09:01
A Quantitative Assessment of the Phagocytosis of Allogeneic and Xenogeneic Erythrocytes by Rat Macrophages In Vitro
0 Views •
2025
This work describes a standardized in vitro protocol to quantify and compare the phagocytosis rates of xenogeneic (human) and allogeneic (rat) red blood cells by isolated rat macrophages.
05:54
Induction of Graft Versus Host Disease in Mouse Models via Allogeneic Bone Marrow and Splenic Cell Transplantation
0 Views •
2025
This video demonstrates the induction of intestinal graft-versus-host disease, GvHD, in a lethally-irradiated recipient mouse using allogeneic hematopoietic stem cells and GvHD-inducing splenic alloreactive T lymphocytes. This protocol helps establish a severe acute intestinal GvHD model to understand the mechanism of the disease and develop innovative therapeutic options.
08:52
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
0 Views •
Cited by 49 •
2011
A rapid, simple and cost-effective protocol for the generation of donor-derived multivirus-specific CTLs (rCTL) for infusion to allogeneic hematopoietic stem cell transplant (HSCT) recipients at risk of developing CMV, Adv or EBV infections. This manufacturing process is GMP-compliant and should ensure the broader implementation of T-cell immunotherapy beyond specialized centers.
11:22
Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
0 Views •
Cited by 32 •
2013
An experimental technique for the treatment of osteochondral defects in the rabbit's knee joint is described. The implantation of allogeneic mesenchymal stem cells into osteochondral defects provides a promising development in the field of tissue engineering. The preparation of fibrin-cell-clots in vitro offers a standardized method for implantation.
FAQs
T cells can respond through two related recognition routes: they may detect foreign major histocompatibility complex, or MHC, molecules directly, or recognize recipient peptides displayed by donor-derived antigen-presenting cells. These signals distinguish transplanted material from self and initiate immune activation. The route involved helps explain why donor-recipient genetic differences are important in transplantation outcomes.
Donor-derived antigen-presenting cells provide the presentation context that allows recipient immune cells to encounter transplantation-associated targets. They can display recipient peptides and contribute to T-cell activation, linking antigen presentation with cytokine release and clonal expansion. Their activity therefore connects the initial recognition event to the broader cellular response that can damage or eliminate grafted tissue.
Recognition of allogeneic targets activates T cells, which release cytokines and undergo clonal expansion. Expanded immune cells can then contribute to cytotoxic pathways, while antibody-mediated pathways may also participate in the response. Together, these effector mechanisms convert recognition into biological injury, helping explain how immune activation can progress from molecular detection to graft rejection.
The direction of immune attack distinguishes these two outcomes. After organ or tissue transplantation, the recipient immune system may attack the graft, producing rejection. Following hematopoietic stem-cell transplantation, immune cells associated with the graft can attack recipient tissues, producing graft-versus-host disease. Both outcomes reflect alloreactivity, but the responding cells and tissues under attack differ.
Donor matching is used to address genetic differences that can influence immune recognition between donor and recipient. Because T cells respond to foreign MHC molecules or presented peptides, closer matching may help reduce the signals that activate alloreactivity. This consideration is especially relevant when evaluating transplantation strategies intended to limit graft rejection or other immune complications.
Immunosuppressive therapy is used to limit the immune activation that follows allogeneic recognition. By reducing the consequences of cytokine release, clonal expansion, and cytotoxic or antibody-mediated effector activity, treatment can help control graft-directed injury. Its relevance extends across transplantation settings, where managing alloreactivity is necessary to support graft survival and reduce immune complications.
Cellular therapies must account for the possibility that immune cells or tissues from a genetically different individual will be recognized as non-self. Such recognition can activate pathways associated with graft rejection or graft-versus-host disease, depending on the transplantation context. Understanding these responses helps guide the development of cellular treatments designed to reduce harmful immune reactions.